VivoSeq
Ophthalmology

Wet Age-Related Macular Degeneration

34

Pipeline Programs↗

3

Active Trials↗

20

Companies Involved↗

Wet Age-Related Macular Degeneration is a moderately active landscape with 34 programs across 20 companies. The most active players are Kyowa Kirin Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. 1 therapy is approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

91/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

1 program

Phase 1Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 1S

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

1 program

Phase 1C

Chengdu Kanghong Biotech Co., Ltd.

1 program

Phase 2F

Fujian Haixi Pharmaceuticals Co., Ltd.

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

78%

Small molecule

31 of 40 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody718%Protein / enzyme25%

Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 98% of 44 pipeline programs.

Analysis

Trial Status

62

clinical trials

Completed48 · 77%
Unknown status6 · 10%
Terminated4 · 6%
Active, not recruiting2 · 3%
Recruiting1 · 2%
Withdrawn1 · 2%

Clinical Trials

Trial Activity

62 trials

Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)
Recruiting·FFujian Haixi Pharmaceuticals Co., Ltd.·Phase 1/2·NCT07185841·198 enrolled
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
Active, not recruiting·EEyePoint Pharmaceuticals, Inc.·Phase 3·NCT06668064·400 enrolled
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
Active, not recruiting·EEyePoint Pharmaceuticals, Inc.·Phase 3·NCT06683742·400 enrolled
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
Completed·Qilu Pharmaceutical Co., Ltd. logoQilu Pharmaceutical Co., Ltd.·Phase 3·NCT05345236·366 enrolled
A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1/2·NCT03861234·43 enrolled
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
Completed·NNorthern California Retina Vitreous Associates·Phase 1/2·NCT01972763·12 enrolled
Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients
Completed·Bayer logoBayer·N/A·NCT03382587·163 enrolled
Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
Completed·—·Phase 2/3·NCT03034772·52 enrolled
WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination
Completed·AAlcon Research·Phase 2·NCT00992563·35 enrolled
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
Completed·AbbVie logoAbbVie·Phase 2·NCT00775411·44 enrolled
Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes
Completed·MMcMaster University·N/A·NCT01363570·70 enrolled
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
Completed·Regeneron logoRegeneron·Phase 3·NCT00509795·1,217 enrolled
Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration
Completed·RRemeGen Co., Ltd.·Phase 1·NCT03777254·12 enrolled
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Completed·Bayer logoBayer·N/A·NCT01447043·2,609 enrolled
Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration
Completed·AAlkahest, Inc.·Phase 2·NCT03558061·30 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)